FI962377A0 - Humanisoituja vasta-aineita ja niiden käyttö - Google Patents

Humanisoituja vasta-aineita ja niiden käyttö

Info

Publication number
FI962377A0
FI962377A0 FI962377A FI962377A FI962377A0 FI 962377 A0 FI962377 A0 FI 962377A0 FI 962377 A FI962377 A FI 962377A FI 962377 A FI962377 A FI 962377A FI 962377 A0 FI962377 A0 FI 962377A0
Authority
FI
Finland
Prior art keywords
humanized antibodies
humanized
antibodies
Prior art date
Application number
FI962377A
Other languages
English (en)
Swedish (sv)
Other versions
FI962377A (fi
Inventor
Augustine Yee-Tharn Lin
Original Assignee
T Cell Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Cell Sciences Inc filed Critical T Cell Sciences Inc
Publication of FI962377A0 publication Critical patent/FI962377A0/fi
Publication of FI962377A publication Critical patent/FI962377A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI962377A 1993-12-08 1996-06-07 Humanisoituja vasta-aineita ja niiden käyttö FI962377A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939325182A GB9325182D0 (en) 1993-12-08 1993-12-08 Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
PCT/IB1994/000387 WO1995016038A2 (en) 1993-12-08 1994-11-21 Humanized antibodies and uses thereof

Publications (2)

Publication Number Publication Date
FI962377A0 true FI962377A0 (fi) 1996-06-07
FI962377A FI962377A (fi) 1996-07-30

Family

ID=10746330

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962377A FI962377A (fi) 1993-12-08 1996-06-07 Humanisoituja vasta-aineita ja niiden käyttö

Country Status (24)

Country Link
US (1) US5861155A (fi)
EP (1) EP0737250A1 (fi)
JP (1) JPH09509307A (fi)
KR (2) KR100239607B1 (fi)
CN (1) CN1063792C (fi)
AU (1) AU699249B2 (fi)
BR (1) BR9408278A (fi)
CA (1) CA2178622A1 (fi)
CZ (2) CZ287347B6 (fi)
EE (1) EE03271B1 (fi)
FI (1) FI962377A (fi)
GB (1) GB9325182D0 (fi)
HU (1) HUT75553A (fi)
IL (1) IL111926A (fi)
LV (1) LV11631B (fi)
NO (1) NO962346L (fi)
NZ (1) NZ276170A (fi)
PL (1) PL180157B1 (fi)
RU (1) RU2139934C1 (fi)
SG (1) SG48420A1 (fi)
SK (1) SK73596A3 (fi)
UA (1) UA29494C2 (fi)
WO (1) WO1995016038A2 (fi)
ZA (1) ZA949341B (fi)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
CN1064052C (zh) * 1997-09-29 2001-04-04 中国科学院微生物研究所 甲状旁腺素相关蛋白人源化抗体及其制备方法
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
GB9906233D0 (en) * 1999-03-19 1999-05-12 Univ Newcastle Bone formation
WO2002034929A2 (en) * 2000-10-20 2002-05-02 Whitehead Institute For Biomedical Research Expression vectors and uses thereof
JP4381822B2 (ja) * 2002-03-22 2009-12-09 株式会社バイファ 免疫グロブリン親水性ペプチド複合体
US7794716B2 (en) 2002-07-25 2010-09-14 Glenveigh Pharmaceuticals, Llc Antibody composition and passive immunization against pregnancy-induced hypertension
GB0302740D0 (en) * 2003-02-06 2003-03-12 Axis Shield Asa Assay
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
BRPI0418766B8 (pt) * 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
US7741448B2 (en) * 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
KR100740201B1 (ko) * 2005-10-21 2007-07-18 삼성전자주식회사 듀얼 전송 스트림 생성 장치 및 그 방법
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US7901687B2 (en) * 2006-04-28 2011-03-08 Eth Zurich Antibodies for the detection of Bacillus anthracis and vaccine against B. anthracis infections
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
JP5732182B2 (ja) * 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
PT2087002E (pt) * 2006-10-27 2014-11-26 Lpath Inc Composições e métodos para a ligação de esfingosina-1- fosfato
US20110064744A1 (en) * 2007-05-30 2011-03-17 Sabbadini Roger A Prevention and treatment of pain using antibodies to lysophosphatidic acid
EP2164992B1 (en) 2007-05-30 2016-05-04 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP2185176B1 (en) 2007-08-10 2016-07-06 Agency for Science, Technology And Research Vhz for diagnosis and treatment of cancer
US7867497B2 (en) * 2007-09-24 2011-01-11 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses therefor
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EP2331107A4 (en) * 2008-08-08 2011-08-24 Agency Science Tech & Res VHZ FOR DIAGNOSIS AND TREATMENT OF CANCERS
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US20110287088A1 (en) 2008-12-03 2011-11-24 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US20110044990A1 (en) * 2008-12-05 2011-02-24 Sabbadini Roger A Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US20100292443A1 (en) * 2009-02-26 2010-11-18 Sabbadini Roger A Humanized platelet activating factor antibody design using anti-lipid antibody templates
WO2010121093A2 (en) * 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2011103426A2 (en) 2010-02-19 2011-08-25 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CA2822610C (en) 2010-12-21 2019-09-03 Selexys Pharmaceuticals Corporation Use of anti-p-selectin antibodies
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
WO2012129520A1 (en) 2011-03-24 2012-09-27 Texas Tech University System Tcr mimic antibodies as vascular targeting tools
AU2012255143A1 (en) 2011-05-19 2014-02-20 The Regents Of The University Of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
EP2739310B1 (en) 2011-08-05 2018-04-18 Research Development Foundation Improved methods and compositions for modulation of olfml3 mediated angiogenesis
US9561266B2 (en) 2012-08-31 2017-02-07 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP2892544A4 (en) 2012-09-05 2016-11-02 Univ Virginia Patent Found TARGET PEPTIDES FOR THERAPY AND DIAGNOSIS OF COLORECTAL CARCINOMAS
DK2912064T3 (da) 2012-10-24 2019-07-22 Res Found Dev Jam-c-antistoffer og fremgangsmåder til behandling af cancer
AU2013359001A1 (en) 2012-12-13 2015-07-23 The Board Of Regents Of The University Of Oklahoma Target peptides for ovarian cancer therapy and diagnostics
KR20210157418A (ko) 2013-03-27 2021-12-28 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CN114621346A (zh) 2013-08-21 2022-06-14 德克萨斯州大学系统董事会 用于靶向连接蛋白半通道的组合物和方法
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
CN109415437B (zh) 2015-12-02 2022-02-01 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
CN116672445A (zh) 2016-02-26 2023-09-01 德克萨斯大学体系董事会 连接蛋白(Cx)43半通道结合抗体及其用途
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
EP3943508B1 (en) 2016-03-29 2024-01-10 Board Of Regents, The University Of Texas System Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
EP3436480A4 (en) 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
EP3487883B1 (en) 2016-07-20 2023-01-04 Stcube, Inc. Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
SG11201903737PA (en) 2016-10-26 2019-05-30 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
KR20200006985A (ko) 2017-05-12 2020-01-21 오거스타 유니버시티 리서치 인스티튜트, 인크. 인간 알파 태아단백-특이적 t 세포 수용체 및 이의 용도
AU2018277545A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
CA3065301A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
DE112018005145T5 (de) 2017-09-15 2020-07-23 The Regents Of The University Of California Hemmung von aminoacylase 3 (aa3) bei der behandlung von krebs
CN112334485A (zh) 2018-04-06 2021-02-05 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
AU2019261426A1 (en) 2018-04-25 2020-12-03 Cedars Sinai Medical Center Optimized anti-TL1A antibodies
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
US20220195024A1 (en) 2018-11-02 2022-06-23 Oklahoma Medical Research Foundation Monoclonal Antibodies to ELTD1 and Uses Thereof
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2022522662A (ja) 2019-02-21 2022-04-20 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
CA3131014A1 (en) * 2019-02-21 2020-08-27 Andreas Loew Anti-tcr antibody molecules and uses thereof
JP2022521750A (ja) * 2019-02-21 2022-04-12 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
CN116063517A (zh) 2019-10-24 2023-05-05 普罗米修斯生物科学公司 Tnf样配体1a(tl1a)的人源化抗体及其用途
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES
EP4090681A1 (en) 2020-01-17 2022-11-23 Biolegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
KR20230028242A (ko) 2020-04-24 2023-02-28 마렝고 테라퓨틱스, 인크. T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR20230074487A (ko) 2020-08-26 2023-05-30 마렝고 테라퓨틱스, 인크. Trbc1 또는 trbc2를 검출하는 방법
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
CN116867519A (zh) 2020-12-01 2023-10-10 约翰斯霍普金斯大学 治疗t细胞癌症的方法和材料
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
ATE161850T1 (de) * 1989-07-19 1998-01-15 Connetics Corp T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5067193A (en) * 1990-07-26 1991-11-26 Container Graphics Corporation Rotary printing plate washing apparatus
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease

Also Published As

Publication number Publication date
KR100239607B1 (ko) 2000-01-15
JPH09509307A (ja) 1997-09-22
CZ287298B6 (cs) 2000-10-11
PL180157B1 (en) 2000-12-29
SG48420A1 (en) 1998-04-17
WO1995016038A3 (en) 1995-07-06
BR9408278A (pt) 1996-12-17
EP0737250A1 (en) 1996-10-16
UA29494C2 (uk) 2000-11-15
IL111926A0 (en) 1995-03-15
NO962346L (no) 1996-08-06
LV11631B (en) 1997-04-20
IL111926A (en) 2002-07-25
NZ276170A (en) 1998-05-27
SK73596A3 (en) 1997-05-07
RU2139934C1 (ru) 1999-10-20
AU1033395A (en) 1995-06-27
HU9601574D0 (en) 1996-07-29
CA2178622A1 (en) 1995-06-15
GB9325182D0 (en) 1994-02-09
HUT75553A (en) 1997-05-28
ZA949341B (en) 1996-05-24
CN1063792C (zh) 2001-03-28
AU699249B2 (en) 1998-11-26
CN1142855A (zh) 1997-02-12
WO1995016038A2 (en) 1995-06-15
NO962346D0 (no) 1996-06-05
US5861155A (en) 1999-01-19
EE03271B1 (et) 2000-06-15
CZ287347B6 (en) 2000-10-11
KR100258902B1 (en) 2000-06-15
LV11631A (lv) 1996-12-20
KR960706560A (ko) 1996-12-09
FI962377A (fi) 1996-07-30
PL314908A1 (en) 1996-09-30
CZ162896A3 (en) 1997-01-15

Similar Documents

Publication Publication Date Title
FI962377A (fi) Humanisoituja vasta-aineita ja niiden käyttö
DK145493D0 (da) Antistof
DE69232604D1 (de) Antikörperkonstrukte
FI944310A0 (fi) Heteroaryyliamino- ja heteroaryylisuolfonamidosubstituoituja 3-bentsyyliaminometyylipiperidiinejä ja vastaavia yhdisteitä
HU9303026D0 (en) New antibodies and their application
NO921863D0 (no) Antistoffer og anvendelse derav
BR9610109A (pt) Fecho e uso mesmo
NO920523L (no) Ige-reseptor-antistoff
DK0697056T3 (da) Drejekors
DE69322847D1 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
ITMI921571A1 (it) Azaciclo e azabiciclo alchiliden idrossilamine
DE69421212T2 (de) Verstärker mit sequentieller Wirkungsweise
FI1031U1 (fi) En troakar
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
KR940010187U (ko) 관로 표시못
KR940026468U (ko) 인재
GB9210929D0 (en) Monoclonal antibodies and their use
GB9204514D0 (en) Monoclonal antibodies and their use
GB9210944D0 (en) Monoclonal antibodies and their use
GB9210930D0 (en) Monoclonal antibodies and their use
DE69324928D1 (de) Monoklonaler antikörper
SE9200338D0 (sv) Antikroppssubstans
FIU930624U0 (fi) Ja/nej-svarkuvert
GB9118013D0 (en) Monoclonal antibodies and their use
DK251090D0 (da) Antistoffer og anvendelse deraf

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: ASTRA AB